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Avian pathogenic Escherichia coli (APEC) infections are a serious impediment to sustainable poultry production
worldwide. Licensed vaccines are available, but the immunological basis of protection is ill-defined and a need
exists to extend cross-serotype efficacy. Here, we analysed innate and adaptive responses induced by commercial
vaccines in turkeys. Both a live-attenuated APEC O78 ΔaroA vaccine (Poulvac® E. coli) and a formalin-inactivated
APEC O78 bacterin conferred significant protection against homologous intra-airsac challenge in a model of acute
colibacillosis. Analysis of expression levels of signature cytokine mRNAs indicated that both vaccines induced a
predominantly Th2 response in the spleen. Both vaccines resulted in increased levels of serum O78-specific IgY
detected by ELISA and significant splenocyte recall responses to soluble APEC antigens at post-vaccination and
post-challenge periods. Supplementing a non-adjuvanted inactivated vaccine with Th2-biasing (Titermax® Gold or
aluminium hydroxide) or Th1-biasing (CASAC or CpG motifs) adjuvants, suggested that Th2-biasing adjuvants may
give more protection. However, all adjuvants tested augmented humoral responses and protection relative to controls.
Our data highlight the importance of both cell-mediated and antibody responses in APEC vaccine-mediated protection
toward the control of a key avian endemic disease.Introduction
Avian pathogenic Escherichia coli (APEC) cause coliba-
cillosis, a complex of respiratory and systemic diseases
that exert substantial welfare and economic costs on
poultry producers worldwide. Losses are incurred through
premature deaths, condemnation of carcasses at slaughter,
reduced productivity and recurring costs associated with
antibiotic prophylaxis and therapy. A recent longitudinal
survey of broiler flocks in the United Kingdom found evi-
dence of colibacillosis in 39% of dead birds [1], and the
same authors implicated colibacillosis in 70% of deaths of
broiler chicks 2–3 days after placement [2]. A number of
risk factors are known, including prior or concurrent* Correspondence: francis.dziva@sta.uwi.edu
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unless otherwise stated.infection with respiratory viruses or Mycoplasma, stress
and injury associated with formation of a social hierarchy,
onset of sexual maturity and intense laying, and poor
biosecurity, hygiene and ventilation. The control of coliba-
cillosis requires the mitigation of such risk factors, but can
also be partly achieved through vaccination.
A major impediment to the design of effective vaccines
is the remarkable diversity of E. coli associated with avian
disease. Though serogroups O1, O2 and O78 and sequence
types ST23 and ST95 are commonly observed, it is clear
that E. coli has evolved to cause avian disease from diverse
lineages via the acquisition of distinct virulence genes [3,4].
Indeed, we recently reported that a ST23 serogroup
O78 strain differed from the prototype ST95 serogroup
O1 strain by over 1100 chromosomal genes and marked
variation exists in their plasmid repertoire and con-
tent [4-6]. Recent analysis of APEC genome sequencesl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Sadeyen et al. Veterinary Research  (2015) 46:5 Page 2 of 14indicates that they may also possess zoonotic potential
owing to their similarity to E. coli that cause human extra-
intestinal infections, such as ascending urinary tract
infections, sepsis and neonatal meningitis [7-10]. Of
further concern is the emergence of multi-drug resistant
E. coli strains in poultry, including those encoding exten-
ded spectrum beta-lactamases (ESBLs), cephalosporin-
resistance and plasmid-mediated quinolone resistance
(PMQR) [11-15]. This is compounded by evidence of
direct transmission of poultry E. coli strains to humans
[16,17]. Taken together with the burden of avian disease, a
need exists to improve control of APEC in reservoir hosts.
The control of APEC has been largely reliant upon
vaccination with autologous bacterins [18-20], but these
confer short-lived serotype-specific protection and their
effectiveness is blunted by the diversity of E. coli capable
of infecting poultry. Live-attenuated vaccines are pre-
ferable owing to ease of administration and improved
cross-serotype protection and hence are entering the
market [21,22]. Numerous attenuated mutants have been
described and evaluated as candidate live vaccines in
experimental models, though direct comparisons of
these are lacking and their mode of action is not under-
stood [21,23-25].
In a subacute model of APEC O78 infection in tur-
keys, we have shown that clearance of primary infection
is associated with the induction of both humoral and
cell-mediated responses [26]. It is unclear whether such
events are also induced by existing commercial vaccines.
Passively administered antibody either acquired vertically
via egg-yolk [27-29] or administered intravenously [30-32]
can be protective against APEC infection. Vaccination of
turkeys with a low dose of a live virulent strain appeared
to give better protection compared to a heat- or formalin-
inactivated non-adjuvanted vaccine [30]. Whilst such pro-
tection was associated with humoral responses, innate
responses leading to adaptive immunity were not analysed,
and the contribution of cell-mediated immunity in protec-
tion was not measured. Moreover, the use of a virulent
strain or inactivated vaccine without adjuvant does not
reflect commercial practice in poultry production. We
therefore sought to define the innate and adaptive re-
sponses associated with protection conferred by licensed
inactivated and live-attenuated vaccines.
Materials and methods
Bacterial strains, growth media and preparation of
vaccines
E. coli serogroup O78:K80 strain EC34195 was isolated
from a chicken that died of colibacillosis and has been
extensively studied [33]. Deletion of 100 bp of the aroA
gene of this strain gave rise to the live-attenuated vaccine
Poulvac® E. coli presently commercialized by Zoetis for
the control of avian colibacillosis [22]. The lyophilizedPoulvac® E. coli vaccine strain was re-constituted in ster-
ile water to ca. 109 colony-forming units (CFU) per mL
prior to use. A whole cell formalin-inactivated vaccine
based on strain EC34195 was prepared without adjuvant
(hereafter designated bacterin), or with a licensed alumin-
ium hydroxide adjuvant, by a supplier of emergency poultry
vaccines according to standard procedures (Ridgeway
Biologicals Ltd., Compton, UK). A spontaneous nalidixic
acid resistant derivative of EC34195 was produced by plat-
ing approximately 10 log10 colony-forming units (CFU) of
EC34195 on MacConkey agar (Oxoid, Basingstoke, UK)
supplemented with 25 μg/mL nalidixic acid (Mac +Nal).
The subsequent derivative (EC34195nalR) was passaged in
pure culture and confirmed to possess an identical growth
rate, phenotypic characteristics and panel of virulence-
associated genes (cvi/cvaC iss, iucD and tsh) to the par-
ent strain. Strain EC34195nalR was stored at −70 °C in
15% (v/v) glycerol in Luria Bertani (LB) broth until re-
quired. The inoculum of this strain was prepared as de-
scribed [26].
Experimental animals
Animal experiments were conducted according to the
requirements of the Animal (Scientific Procedures) Act
1986 (licence no. 30/2463) with the approval of the
Local Ethical Review Committee. Male Big5FLX turkeys
were obtained from Aviagen Ltd. (Tattenhall, Cheshire,
UK) as day-old poults, housed and reared as previously
described [26].
Analysis of protection conferred by licensed live-attenuated
and whole cell formalin-inactivated APEC O78 vaccines
in turkeys
Thirty 1-day old turkey poults were randomly housed in
groups of 10 birds per room on floor pens to simulate
commercial practice. For the delivery of a coarse aerosol
spray of live vaccine, birds were restrained in one corner
of the room at a density of 10 birds per 0.25 m2, and the
vaccine was administered with a syringe fitted with a de-
vice that creates a coarse aerosol directed at the faces of
individual birds. Group A (control) received 10 mL ster-
ile saline as coarse spray (per group, not individually)
while group B received 10 mL of saline containing 107 CFU
per mL of the Poulvac® E. coli live-attenuated vaccine. Each
bird in group C received 0.2 mL (containing the equivalent
of approximately 2 × 109 CFU) of the EC34195 inactivated
vaccine via the subcutaneous route as per commercial
practice and recommended by the manufacturer. Birds
were monitored for adverse reactions every 3 h for the
first 24 h and thereafter twice daily until the booster vac-
cinations. Birds in group B were given a booster of ca.
107 CFU per mL in drinking water at 7 days of age. Excess
vaccine-treated water was discarded after 18 h. Birds in
group C were given a booster (0.4 mL) of the same
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ous route in the neck region. The control group was
given sterile saline in drinking water mixed at the same
proportions as for the live vaccine. Birds were moni-
tored twice daily for the remainder of the experiment.
On day 41 post-primary vaccination, all the birds were
inoculated into the left caudal thoracic airsac with
107 CFU of the EC34195nalR strain, on which both vac-
cines are based, in 100 μL of saline and monitored over-
night for clinical signs. After 24 h, all the birds were killed
humanely and subjected to post-mortem examination
essentially as described [26]. Part of the spleen was collec-
ted for T cell re-stimulation assays. Lung, liver, kidney and
the remaining spleen tissue were sampled to enumerate
tissue-associated bacteria whilst blood and bile were
collected for serology.
Analysis of innate and adaptive responses upon
vaccination with licensed live-attenuated and inactivated
APEC O78 vaccines in turkeys
Having established vaccine efficacy in pilot studies
(above), one hundred and thirty-five 1-day old turkey
poults were randomly divided into 3 groups of 45 birds
and housed separately. Birds were vaccinated as described
above with sterile saline (control group), Poulvac® E. coli
or inactivated vaccine with aluminium hydroxide adjuvant.
Boosters were given at the respective time-points as above.
On days 1, 3, 5, 7, 14, 21 and 28 post-primary vaccination,
five birds were randomly removed from each group, killed
humanely and subjected to post-mortem examination.
From each bird, sections of liver, lung and spleen were
collected in RNAlater (Ambion, Warrington, UK) for cy-
tokine analysis. In the live vaccine group, the remainder of
the lung was used to enumerate the vaccine strain as
described below. Selected colonies were subjected to PCR
analysis spanning the aroA gene using the primers (aroA-
F-TTGAGTTCGAACGTCGTCAC and aroA-R-GCAA
TGTGCCGACGTCTTTG) and agglutination with spe-
cific anti-O78 serum (AHVLA, Weybridge, UK) to confirm
recovery of the vaccine strain. At day 28 post-primary vac-
cination, the spleen was collected into ice-cold RPMI1640
medium for use in T cell re-stimulation assays and blood
and bile were collected for serology. On day 41 post-
primary vaccination, all the remaining birds were chal-
lenged, subjected to post-mortem examination 24 h later
and tissues sampled as described above.
Total RNA extraction and real-time quantitative RT-PCR
for cytokine mRNA
Total RNA extraction and cytokine mRNA analyses were
performed essentially as described [26]. Data are expressed
in terms of the cycle threshold value (Ct), normalised for
each sample using the Ct value of 28S rRNA product for
the same sample, as described previously [34,35]. Finalresults are shown as corrected ΔCt, using the normal-
ised value.
Enumeration of tissue-associated bacteria
Viable tissue-associated bacteria were enumerated essen-
tially as described [4]. The lower limit of detection by this
method was 1.79 log10 CFU/g of tissue. Enrichment cul-
tures were also performed in which 1 mL of tissue hom-
ogenate was cultured in 9 mL brain heart infusion (BHI)
broth for 18 h at 37 °C aerobically, prior to plating on
Mac +Nal, giving a theoretical lower limit of detection by
enrichment of 1 log10 CFU/g of tissue.
Measurement of antibody and cell-mediated responses
Preparation of APEC soluble antigens for ELISA, quanti-
fication of total protein content, storage and subsequent
antibody assays were performed essentially as described
[26]. Cell-mediated responses were determined by sple-
nocyte proliferation assays again as previously de-
scribed [26] and data is expressed as mean counts per
minute (cpm).
Analysis of a bacterin mixed with Th1- or Th2-biasing
adjuvants
The Th1-stimulating adjuvant CASAC: (combined ad-
juvant synergistic activation of cellular immunity) was
formulated by an adaptation of the method described
[36]. Briefly, the first dose comprised 50 μg of mono-
phosphoryl lipid A (MPL; Invivogen, Toulouse, France),
50 μg of Pam3CysSerLys4 (Pam3CSK4; EMC Microcol-
lections, Tuebingen, Germany) and 50 μg of chicken
interferon-γ (2B Scientific, Upper Heyford, UK) ho-
mogenized with 100 μL (same dose as previously used)
of formalin-inactivated EC34195 supplied to commercial
specification by Ridgeway Biologicals Ltd. but without
adjuvant (bacterin). The booster comprised the same
ingredients of CASAC mixed with 200 μL of bacterin.
Bacterin formulated with a second Th1-biasing adjuvant
was separately prepared using synthetic cytosine phospho-
diester-guanine (CpG)-containing oligodeoxynucleotides
(ODN) as described [37]. The sequence for CpG-ODN,
TCGTCGTTTGTCGTTTTGTCGTT (bold motifs en-
hance CpG-ODN activity), was synthesized with a phos-
phothionate backbone (Sigma). The first dose was
prepared by mixing 20 μg of synthetic CpG-ODN (in
sterile pyrogen-free water) with 100 μL of the non-
adjuvanted EC34195 bacterin. The booster dose comprised
the same amount of CpG-ODN in 200 μL of non-
adjuvanted EC34195 bacterin.
For comparison, the formalin-inactivated bacterin with-
out adjuvant was also formulated with Th2-stimulating
adjuvants. The first of these comprised a dose of 100 μL
of EC34195 bacterin thoroughly mixed with an equal
volume (ratio of 1:1) of Titermax® Gold (Sigma) as per
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of the homogenous mixture. EC34195 bacterin formulated
with aluminium hydroxide adjuvant was also tested as
another Th2-stimulating adjuvant; 100 μL for primary
vaccination and 200 μL for the booster (same dose as in
the pilot studies).
For vaccination, thirty 1-day old turkey poults were
randomly divided into 6 groups of 5 birds and housed
separately as before. Group 1 received sterile saline (nega-
tive control group), group 2 received formalin-inactivated
EC34195 bacterin without adjuvant (control group), group
3 received the same bacterin formulated with CpG-ODN,
group 4 received the same bacterin with CASAC, group 5
received the same bacterin mixed with aluminium hy-
droxide, group 6 received the same bacterin mixed with
Titermax® gold. All vaccines were administered by the
subcutaneous route with booster doses for the respective
vaccine formulations given at 14 days of age via the same
route. Birds were monitored twice daily for the duration
of the experiment. On day 41 post-primary vaccina-
tion, all the birds were inoculated with 107 CFU of strain
EC34195nalR in 100 μL of saline into the left caudal thor-
acic airsac as above and monitored overnight for clinical
signs. All the birds were killed humanely and subjected to
post-mortem examination and collection of organs and
blood as above.
Statistical analyses
Cytokine data was analysed for statistical significance
using a one-way ANOVA test with an ad hoc Tukey’s test.
Bacterial counts recovered from tissues, antibody levels
and splenocyte recall responses were analysed by Student’s
t-test. P values ≤ 0.05 were considered significant.
Results
Licensed live-attenuated and formalin-inactivated
vaccines based on APEC O78 are protective against
homologous challenge in turkeys
To evaluate the protective efficacy of existing vaccines
and establish models in which the basis of protection
can be dissected, turkeys were vaccinated using Poulvac®
E. coli or an inactivated vaccine based on the parent strain
of Poulvac® E. coli and compared to mock-vaccinated tur-
keys. In birds given the live vaccine, up to ca. 4 log10 CFU
per gram lung tissue of the vaccine strain was detected 1,
3, 5 and 7 days post-primary vaccination (data not shown).
Recovery of the vaccine strain was confirmed by a specific
PCR for the aroA gene in E. coli isolated from the lung
homogenates at these times (data not shown). The live-
attenuated vaccine strain was not detectable at any other
time-points in any group.
Upon intra-airsac challenge of vaccinated birds with a
nalidixic acid resistant derivative of the strain used to
prepare the vaccines, significant protection was observedin the groups that received either Poulvac® E. coli or the
inactivated vaccine (Figure 1). Approximately 4 log10
CFU/g EC34195nalR were recovered from the lung, liver,
spleen and kidney of mock-vaccinated turkeys. In con-
trast, nalidixic acid resistant E. coli were only detectable
in the spleens, livers and kidneys of turkeys that received
the inactivated vaccine by enrichment, where the theoret-
ical lower limit of detection was 1 log10 CFU/g (Figure 1;
P < 0.05). The number of nalidixic acid resistant E. coli re-
covered from the lung, liver, spleen and kidney of turkeys
that received the live vaccine was significantly reduced by
around 2 log10 CFU/g (Figure 1; P < 0.05). Consistent with
the lower numbers of bacteria recovered from the organs
of vaccinated birds after challenge with EC34195nalR,
none of the vaccinated birds exhibited clinical signs or
pathological lesions indicative of colibacillosis as previ-
ously defined [26]. By contrast, all mock-vaccinated birds
challenged with EC34195nalR exhibited clinical signs typ-
ical of colibacillosis (respiratory distress, hunched posture,
ruffled feathers, reduced response to stimulus) and gross
post-mortem lesions including airsacculitis, pericarditis,
perihepatitis and fibrin deposits on serosal surfaces at 24 h
post-challenge. It can therefore be inferred that the strain
is virulent and that live-attenuated or inactivated vaccines
derived from it confer protection against homologous
re-challenge.
Quantification of cytokine transcripts indicates that
licensed live-attenuated and inactivated APEC O78
vaccines predominantly induce a Th2 response in the
spleen of turkeys
To assess cytokine responses as signatures of innate and
adaptive immune responses induced by the live-attenuated
and inactivated vaccines, turkey poults were vaccinated as
above and killed at intervals. We analysed the levels of
transcripts encoding a pro-inflammatory cytokine (IL-1β),
a pro-inflammatory chemokine (CXCLi2), a signature Th1
cytokine (IFN-γ), a signature Th2 cytokine (IL-13) and two
signature T regulatory cytokines (IL-10 and TGF-β4), at
intervals post-primary and -secondary vaccination.
The normalised levels of transcripts encoding these
cytokines are shown over time in the spleen (Figure 2),
liver (Figure 3) and lung (Figure 4). In the spleen, the
live-attenuated and inactivated vaccines significantly in-
duced transcription of IL-13 in the first week post-
primary vaccination (Figure 2; P < 0.05). In the same
period, transcription of the signature Th1 cytokine IFN-γ
was significantly repressed following vaccination rela-
tive to levels in the mock-vaccinated controls (Figure 2;
P < 0.05), and transcription levels of the anti-inflammatory
cytokine TGF-β4 (the chicken equivalent of mammalian
TGF-β1) were significantly induced following vaccination
(Figure 2; p < 0.05). Together, these data indicate a bias
towards a Th2 response at a key site of immune priming
Figure 1 Recoveries of strain EC34195nalR from organs of vaccinated turkeys at 24 h post-challenge. Turkey poults were given sterile
saline (mock) as a coarse spray (open bars), a formalin-inactivated vaccine of the parent strain EC34195 formulated in aluminium hydroxide adjuvant
via the subcutaneous route (black bars) or Poulvac® E. coli as a coarse spray (checked black and white bars) starting at one day-old as indicated in the
Materials and methods. All turkeys were challenged via the intra-airsac route at day 41 post-primary vaccination with EC34195nalR and the indicated
tissues recovered 24 h later. The data are expressed as mean log10 CFU/g tissue ± standard error of the mean. The limit of detection by direct plating
was 1.79 and limit of detection by enrichment was 1 log10 CFU/g tissue; + denotes values after enrichment of tissue homogenates. *denotes P≤ 0.05
relative to mock-vaccinated controls.
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immune response to primary vaccination.
In the other two organs, the pattern is less clear.
Elevated IL-13 mRNA expression levels were also detec-
ted in the liver (Figure 3) and lung (Figure 4), but only
at a couple of time-points and with no discernible pat-
tern in the first week post-primary vaccination with
live-attenuated or inactivated vaccines. In the lung,
IFN-γ transcription was generally lower in turkeys given
the live-attenuated vaccine compared to mock-vaccinated
birds, significantly so at multiple time-points (Figure 4).
However, the inactivated vaccine only significantly re-
pressed IFN-γ transcription in the lung at 21 and 28 days
post-primary vaccination, time-points which would rep-
resent the resolution of a normal adaptive immune
response to primary vaccination (Figure 4). No repression
of IFN-γ transcription was detected in the liver at any
time-point (Figure 3). In both organs, we detected signifi-
cant induction of TGF-β4 mRNA expression in turkeys
vaccinated with the live-attenuated or inactivated vaccines,
particularly in the first two weeks post-primary vaccina-
tion (Figures 3 and 4; P < 0.05).
Differences between groups in transcription of the other
cytokines analysed did not show consistent trends across
organs or time in vaccinated turkeys relative to controls,
with the exception of CXCLi2 expression, which was un-
altered following vaccination in the spleen (Figure 2), con-
sistently down-regulated in the lung (Figure 4; P < 0.05)
and generally up-regulated in the liver (Figure 3; P < 0.05).
CXCLi2 mainly chemo-attracts monocytes [35], and thisdifferential expression may reflect traffic of these cells in
response to vaccination.
Vaccine-induced protection against homologous
challenge is associated with elevated adaptive responses
To identify adaptive immune responses associated with
protection against homologous challenge induced by each
vaccine, we measured humoral and cellular responses at
intervals after primary and secondary vaccination of tur-
keys using samples from the same birds as used for cyto-
kine analysis. Immunoglobin Y (IgY) levels and splenocyte
proliferation responses were measured in birds killed at
day 28 and after challenge (day 42) whereas IgA in bile
was measured 24 h after challenge. Both vaccines induced
elevated IgY levels post-primary vaccination relative to the
mock-vaccinated group, for the inactivated vaccine at
both intervals and for the live-attenuated vaccine at day
42 (Figure 5A; P ≤ 0.05). APEC-specific IgA was elevated
in bile from poults given the inactivated vaccine relative
to the mock-vaccinated group (Figure 5B; P ≤ 0.05).
The ability of splenocytes recovered from each group
to proliferate in response to mitogen or soluble EC34195
antigen was also evaluated at day 28 post-primary vaccin-
ation and at post-mortem examination on day 42 (24 h
after challenge). The response to ConA was comparable
between the birds given mock- or inactivated vaccine at
day 28, and was not significantly different from control
birds in the group given Poulvac® E. coli (Figure 6A). After
challenge, almost no proliferation of splenocytes from the
control group was seen in response to ConA (Figure 6A),
Figure 2 Levels of cytokine transcripts in the spleens of vaccinated turkeys as measured by real-time qRT-PCR. Results are expressed as
corrected ΔCt values ± standard error of the mean after normalization with the Ct value of 28S rRNA product of each sample. Turkey poults were
given sterile saline (mock) as a coarse spray (open bars), a formalin-inactivated vaccine based on the parent strain EC34195 formulated in aluminium
hydroxide adjuvant via the subcutaneous route (black bars) or Poulvac® E. coli as a coarse spray (checked black and white bars) starting at one day-old.
Five birds from each group were sampled per time-point. *denotes P≤ 0.05 relative to mock-vaccinated controls.
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fection detected following primary and secondary in-
fection [26]. Splenocytes recovered from birds given
live-attenuated or inactivated vaccines at day 42 prolifer-
ated in response to ConA (Figure 6A).
Splenocyte proliferation in response to APEC soluble
antigen was significantly elevated both vaccinated groups
at day 42 relative to levels in the mock-vaccinated group
(Figure 6B, P < 0.05). Responses were lower in the group
given the live-attenuated vaccine relative to the controlgroup at day 28 and relative to the inactivated vaccine
group at both time-points. At day 42, no response to
EC34195 soluble antigen was seen in the control group.
Impact of Th1- and Th2-stimulating adjuvants on protection
conferred by the APEC O78 inactivated bacterin
To examine the effects of Th1- and Th2-stimulating ad-
juvants, we formulated the EC34195 inactivated bacterin
with two compounds with a reported bias toward Th1
responses (CASAC or CpG) and two with a reported
Figure 3 Levels of cytokine transcripts in the livers of vaccinated turkeys as measured by real-time qRT-PCR. Details are as in the legend
to Figure 2.
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Gold) [36,38,39]. The vaccines were given to day-old turkey
poults and again 14 days later by the subcutaneous route,
with intra-airsac challenge with EC34195nalR at day 41, as
described in pilot studies where protection conferred by
the inactivated vaccine was shown (Figure 1). A bacterin
without adjuvant and mock-vaccination with saline were
used as controls.
At 24 h post-challenge, statistically significant reduc-
tions in the numbers of EC34195nalR recovered from
the liver and kidney were observed in birds vaccinatedwith bacterin formulated with either CASAC or CpG
oligonucleotides as adjuvants, and in the spleen of birds
vaccinated with CpG oligonucleotides, relative to levels
in the mock-vaccinated group (Figure 7A; P < 0.05). In
the groups that received the bacterin formulated with
CASAC or CpG, there was also a significant reduction
in bacterial numbers in the liver relative to the group
that received the bacterin alone, but this difference was
not seen in the spleen, kidney or lung (Figure 7A).
In the turkeys vaccinated with the bacterin formulated
with the Th2-stimulating adjuvants aluminium hydroxide
Figure 4 Levels of cytokine transcripts in the lungs of vaccinated turkeys as measured by real-time qRT-PCR. Details are as in the legend
to Figure 2.
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isolated from the liver, kidney and spleen on direct plating
(Figure 7B), but they were detected by enrichment of ho-
mogenates of these organs (a theoretical limit of detection
of 1 log10 CFU/g). Differences in bacterial numbers were
statistically significant in all organs from the group that
received bacterin formulated with TiterMax® relative to
either the bacterin alone or mock-vaccinated control
groups (P < 0.05). Significant reductions in bacterial
numbers were also seen in the liver, spleen and kidney
of birds that received the bacterin with aluminium hy-
droxide relative to the groups that received mock, bac-
terin alone, or bacterin formulated with CASAC or CpG
(Figure 7A and B).On analysis of APEC-specific IgY at 42 days post-
primary vaccination, the bacterin alone induced signifi-
cantly elevated APEC-specific IgY levels relative to mock
vaccinated birds (Figure 7C; P < 0.05). The magnitude of
the APEC-specific IgY response was no greater when the
bacterin was formulated with CpG and marginally lower
when formulated with CASAC relative to bacterin alone
(Figure 7C). Levels of APEC-specific IgY were no greater
in the groups that received the bacterin formulated with
aluminium hydroxide and marginally greater when for-
mulated with TiterMax® compared to the bacterin alone
(Figure 7D). There is therefore a suggestion that these
Th2-biasing adjuvants might generate greater levels of
APEC-specific IgY response than Th1-biasing adjuvants.
Figure 5 APEC-specific antibody responses in vaccinated turkeys before and after challenge. Turkey poults were given sterile saline (mock)
as a coarse spray (open bars), a formalin-inactivated vaccine based on the parent strain EC34195 formulated in aluminium hydroxide adjuvant via
the subcutaneous route (black bars) or Poulvac® E. coli as a coarse spray (checked black and white bars) starting at one day-old. Five birds from
each group were sampled at day 28 post-primary vaccination and 10 birds per group at day 42 post-primary vaccination (24 h after intra-airsac
challenge with EC34195nalR) and serum IgY (A) and bile IgA (B) levels determined by an APEC-specific ELISA. *denotes P ≤ 0.05 relative to
mock-vaccinated controls.
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We recently analysed innate and adaptive responses in-
duced by primary APEC O78 infection and demonstrated
an association of these with protection against homolo-
gous re-challenge [26]. Here, we extended our studies to
dissect the immune responses induced by licensed APEC
O78-based live-attenuated and inactivated vaccines and
their association with protection. We verified that the two
vaccines (Poulvac® E. coli and a formalin-inactivated vac-
cine based on its parent strain prepared to commercial
specifications) were protective against homologous intra-
airsac challenge with EC34195nalR of turkeys (Figure 1)
before examining vaccine-induced innate and adaptive
responses. Protection was observed both at the level of
clinical signs and the appearance of gross post-mortem
lesions typical of colibacillosis, as well as the burden of the
challenge strain in the lungs and visceral organs. Whilst
we were reliably able to detect vaccine-mediated protec-
tion against systemic disease and lung colonisation in the
turkey model, we acknowledge that it relies on homolo-
gous challenge with high doses instilled directly into the
left caudal airsac. The basis of protection may therefore
differ when turkeys are challenged by heterologous APEC
via other routes or natural exposure, and indeed may dif-
fer in other avian species. We also acknowledge that the
protection observed is largely against bacterial replication
in internal organs after systemic translocation of APEC
rather than at mucosal surfaces, as the model mimics theoften fatal form of avian colibacillosis but not superficial
or subacute infections where limited invasion occurs.
Variance between the birds receiving the live-attenuated
vaccine by coarse spray and in the drinking water was lim-
ited, implying that reasonably uniform doses were given
despite the inherent limitations of the mode of delivery.
We recovered consistent numbers of the Poulvac® E. coli
strain from the lung and internal organs of vaccinated
birds, and confirmed isolates had the expected genotype.
The protection observed is consistent with a recent study
by the producers of the vaccine strain [22]. Although vac-
cination of birds less than 2 weeks of age against E. coli
can lead to poor protection, which is thought to be due to
the relative immaturity of their immune system at that
point [27], our protocol adhered to the recommended
practice described for Poulvac® E. coli [22], and we believe
that the protective responses observed in our models are
such that an evaluation of the role of innate and adaptive
responses in the protection observed is justified.
Inactivated vaccines based on formalin- or heat-
inactivated E. coli are generally believed to confer protec-
tion against avian colibacillosis in an antibody-dependent
manner [30,40]. This has been partly established through
passive transfer of hyper-immune serum [29-32] or egg-
yolk antibody [27,28,41]. However, cytokine responses to
APEC vaccination have not previously been analysed.
Similarly, whilst live-attenuated mutants of various kinds
can confer resistance against APEC in target host species
Figure 6 Turkey splenocyte proliferation responses to Concanavalin A and EC34195 soluble lysate in vaccinated turkeys before and
after challenge. Turkey poults were given sterile saline (mock) as a coarse spray (open bars), a formalin-inactivated vaccine based on the parent
strain EC34195 formulated in aluminium hydroxide adjuvant via the subcutaneous route (black bars) or Poulvac® E. coli as a coarse spray (checked
black and white bars) starting at one day-old. Five birds were sampled from each group at each time and splenocytes re-stimulated with ConA
(A) or EC43195 soluble lysate (B). The data are presented as mean counts per minute ± standard error of the mean. *denotes P ≤ 0.05 relative to
mock-vaccinated controls.
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they elicit are ill-defined. Studies by Fernandez Filho et al.
[43] with Poulvac® E. coli only examined peripheral cellu-
lar responses to vaccination, with a fine spray, of day-old
chicks. No booster was given to those birds at 7 days of
age via drinking water as is recommended [22]. A recent
field trial of Poulvac® E. coli [42] also supports that giving
a booster in drinking water is not necessary. Interestingly,
a higher level of peripheral B lymphocytes was detected in
the control than the vaccinated group and the authors
speculated that Poulvac® E. coli may suppress humoral
responses and that they may therefore be dispensable in
protection [43]. In support of this, Salehi et al. [44] also re-
ported a lack of significant induction of antibody response
in chickens after aerosol administration of an independent
aroA mutant of E. coli. In contrast, we observed that
Poulvac® E. coli elicited significantly elevated APEC-specificserum IgY in turkeys relative to mock-vaccinated poults.
Differences between this study and earlier reports could of
course be due to variations in the vaccination protocols, in
particular the administration of single dose of the vaccine
when birds are still immunologically immature.
The induction of APEC-specific humoral responses by
both vaccines in this study is supported by analysis of
transcription of cytokines and chemokines at a key site
of immune priming, the spleen. In the spleen, during the
first week post-vaccination, transcription of the signature
Th1 cytokine IFN-γ was repressed, whereas that of the
signature Th2 cytokine IL-13 was significantly induced
by both vaccines. Reduced transcription of IFN-γ was
also seen in the lung at multiple time-points after vaccin-
ation with the live-attenuated vaccine but was not evident
in the liver. IL-13 mRNA expression levels in the lung and
liver in the first week post-primary vaccination showed no
Figure 7 Recoveries of strain EC34195nalR from organs of turkeys vaccinated with a formalin-inactivated bacterin formulated with
different adjuvants at 24 h post-challenge. Turkey poults were given sterile saline (negative control), an EC34915-based inactivated bacterin
without adjuvant, or formulated with adjuvants that promote a Th1 response (CASAC or CpG-oligonucleotides (A)), or Th2 response (Titermax®
Gold or aluminium hydroxide (B)). All vaccines were given by the subcutaneous route at 1 day-old and boosted at day 14. All the birds were
challenged at day 41 post-primary vaccination via the intra-airsac route with EC34195nalR and sampled after 24 h. The data are presented as mean log10
CFU/g tissue ± standard error of the mean. APEC-specific serum IgY levels for corresponding birds at post-mortem examination were measured by ELISA
compared to mock- and bacterin-vaccinated groups, Th1- (C) and Th2-stimulating adjuvants (D). + denotes value of EC34195nalR after enrichment. “a”
denotes P≤ 0.05 relative to turkey poults that received sterile saline (mock-vaccinated group), “b” denotes P≤ 0.05 relative to bacterin alone, and “ab” is
significance relative to both mock- and bacterin-vaccinated groups.
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organs could be suggestive of a proliferative cellular re-
sponse that requires some kind of regulation. Transient
expression of IL-6 was observed in the first 5 days in the
spleen, but not liver or lung (data not shown). Since the
nature of such proliferative cellular responses could not
be discerned, we reasoned that TGF-β4 acted primarily as
an anti-inflammatory suppressing the expression of IL-6
in all organs. Overall, the data are indicative of a Th2-
biased response to vaccination in the spleen, albeit this is
less evident in the liver and lung. The magnitude of cyto-
kine responses was not markedly different between the
live-attenuated and inactivated vaccine groups and there-
fore cannot readily be associated with the magnitude of
the adaptive responses measured.
After challenge, splenocyte recall responses to ConA
or APEC-specific antigens in the control group (with a
high bacterial recovery in the spleen) were poor and
absent respectively. These data are consistent with the
suppressive effect of APEC O78 on proliferative respon-
ses detected in our earlier studies [26], and may imply
that the live-attenuated vaccine also has a negative effect
on the capacity of splenocytes to proliferate in response
to mitogen. As the live-attenuated vaccine could not be
recovered from vaccinated turkey poults at day 28, it is
difficult to separate the extent to which proliferativeresponses are an accurate reflection of recall responses,
or were compromised owing to presence of low numbers
of bacteria or their products. The possibility of suppressive
effects makes it difficult to interpret the response in the
group given the inactivated vaccine at day 42, as the
spleen was recovered after challenge of such birds. Earlier
evidence suggests that inactivated vaccines are poor in-
ducers of T cell-mediated immunity [45]. However, we
detected significantly elevated splenocyte proliferative
responses to APEC-specific antigens induced by the
inactivated vaccine after challenge. Studies with a killed
Salmonella vaccine have also shown a significant induc-
tion of lympho-proliferative responses, though these were
age- and antigen-dependent [46]. APEC membrane vesi-
cles can evoke both antibody production and T cell
proliferation and specifically stimulate T cytotoxic cells to
confer resistance against APEC [47], further indicating
that inert APEC vaccines can stimulate both adaptive
pathways.
Given the potential importance of the Th2 pathway in
protection conferred by the vaccines tested, we evaluated
the effects of Th1- and Th2-stimulating adjuvants
using an EC34195-based bacterin. This enabled us to
standardize the dose and timing and compare protec-
tion observed without adjuvant with that given by bacterin
formulated with aluminium hydroxide that had already
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Th1 adjuvants resulted in significant reduction in bacterial
numbers recovered from internal organs relative to the
control (mock-vaccinated) group, the Th2 adjuvants elic-
ited better protective responses in the lungs (especially
TiterMax®) and internal organs. CpG-ODN induce pre-
dominantly a Th1 response [38,39,48], and administration
of these on their own 3 days prior to challenge confers
protection against E. coli infections in neonatal and adult
chickens [49,50]. Furthermore, formulating an inactivated
vaccine with these motifs imparted a more potent effect in
halting the spread of a lethal APEC strain [51], implying
the importance of Th1 responses in resistance against
APEC. In this study CpG-ODN did not significantly
augment humoral responses or protection relative to
the bacterin alone, except in the liver. CASAC is a recently
described potent Th1-stimulating adjuvant consisting
of three components [36], including interferon-gamma
(IFN-γ). We used chicken IFN-γ owing to its commercial
availability, and is biologically cross-reactive in the turkey
[52]. As with CpG, CASAC did not potentiate humoral
responses or protection relative to those seen with the
bacterin alone, except in the liver. One of the Th2-biasing
adjuvants (TiterMax®) gave significantly improved protec-
tion relative to the bacterin alone as well as significantly
elevated APEC-specific IgY levels, whereas the other (alu-
minium hydroxide) was not different to responses to the
bacterin alone, in accordance with earlier reports [18,20].
While it is not conclusively clear if Th2 adjuvants stimu-
late more potent antibody responses and protection than
Th1 adjuvants in the context of inactivated APEC vac-
cines, the data suggest that further research to augment
Th2 responses has merit.
In conclusion, we show that live and inactivated APEC
vaccines are protective against experimental intra-airsac
challenge in a turkey model of acute colibacillosis and
that they both induce predominantly a Th2 response in
the spleen that correlates with elevated APEC-specific
antibody levels. Whilst we have defined the responses
associated with vaccine-mediated protection against
homologous challenge, the relative contribution of humoral
and cell-mediated immunity in protection against heterol-
ogous APEC infection requires further study. Demonstra-
tion of a key role for antibody will help to prime reverse
vaccinology to identify conserved surface-exposed constit-
uents of APEC that can elicit antibody to fix complement
and prime phagocytosis. Although our recent sequencing
of APEC indicates that E. coli evolve to cause avian disease
from varied lineages via acquisition of distinct sets of viru-
lence genes, we also revealed a core genome encoding of
over 3000 conserved factors [4]. Mining of the core gen-
ome of human extraintestinal pathogenic E. coli strains
has yielded a subset of factors that show promise as cross-
protective vaccines for control of sepsis and urinary tractinfections [53,54], and a similar approach for avian coliba-
cillosis has merit. The models and data presented here will
help to inform and evaluate improved vaccines in target
hosts.
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